10-14 April, 2019
ENYO Pharma team was present in Vienna from the 10th to the 14th of April at the EASL congress on liver diseases. On this occasion, several and fruitful discussions with various players took place. It was also the opportunity to present, in collaboration with the French research institut Inserm, a poster on the role of FXR and FXR agonists in the recruitment of HBx protein on HBV DNA.
26-28 March, 2019
ENYO Pharma has attended the China Healthcare Investment Conference from the 26th to the 28th of March, 2019. It was a great opportunity to initiate several financing and partneurship discussions.
7 – 10 January, 2019
San Francisco, USA
“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.” (jpmorgan.com)
10 – 11 December, 2018
ENYO Pharma’s CSO Eric Meldrum is participating today at the I4ID Congress (Immunotherapies for Infectious Diseases Congress) in Lyon, France. I4ID Congress is dedicated to Host-Directed Therapies to fight infectious diseases. During this event, Eric will present new data from ENYO Pharma preclinical programmes to exemplify the power of ENYO Pharma’s drug discovery approach.
“The 2nd edition I4ID2018, follows the success of the first edition,
4 – 5 December, 2018
ENYO Pharma’s CEO Jacky Vonderscher has been invited to speak in the conference programme of BioFIT 2018 in Lille, France, on December 4th and 5th. He had the opportunity to share his experience and knowledge during the following session – agnostic or pure players in the biotech sector: who is becoming prominent in the early-stage financing rounds? He was also able to give ENYO’s experience feedback following the first fundraising in 2016.